Serveur d'exploration H2N2

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Influenza

Identifieur interne : 001996 ( Main/Exploration ); précédent : 001995; suivant : 001997

Influenza

Auteurs : Nancy J. Cox [États-Unis] ; Kanta Subbarao [États-Unis]

Source :

RBID : ISTEX:E3DD38D50833B0C3308A0D61F6E108953AF09969

English descriptors

Abstract

Summary: Influenza is the most frequent cause of acute respiratory illness requiring medical intervention because it affects all age groups and because it can recur in any individual. During the past three decades, efforts to prevent and control influenza have focused primarily on the use of inactivated influenza vaccines in elderly people and in individuals with chronic medical conditions that put them at risk for complications. However, the continuing impact of influenza in these and other population groups has motivated the development of novel approaches for prevention and control of influenza. Several important advances in the field of influenza have occurred in the last few years. An experimental live, attenuated, intranasally administered trivalent influenza vaccine was shown to be highly effective in protecting young children against influenza A H3N2 and influenza B. New antiviral drugs based on the structure of the neuraminidase molecule were assessed in clinical trials and found to be effective against influenza A and B viruses. The expected use of these new antiviral agents has accelerated the development of rapid point-of-care diagnostic tests. The availability of new diagnostic tests, new antiviral drugs, and new vaccines will undoubtedly alter our approaches to influenza control and have an impact on clinical practice.

Url:
DOI: 10.1016/S0140-6736(99)01241-6


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title>Influenza</title>
<author>
<name sortKey="Cox, Nancy J" sort="Cox, Nancy J" uniqKey="Cox N" first="Nancy J" last="Cox">Nancy J. Cox</name>
</author>
<author>
<name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:E3DD38D50833B0C3308A0D61F6E108953AF09969</idno>
<date when="1999" year="1999">1999</date>
<idno type="doi">10.1016/S0140-6736(99)01241-6</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-6LF81M92-N/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001304</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001304</idno>
<idno type="wicri:Area/Istex/Curation">001304</idno>
<idno type="wicri:Area/Istex/Checkpoint">000796</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000796</idno>
<idno type="wicri:Area/Main/Merge">001A43</idno>
<idno type="wicri:Area/Main/Curation">001996</idno>
<idno type="wicri:Area/Main/Exploration">001996</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a">Influenza</title>
<author>
<name sortKey="Cox, Nancy J" sort="Cox, Nancy J" uniqKey="Cox N" first="Nancy J" last="Cox">Nancy J. Cox</name>
<affiliation></affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">The Lancet</title>
<title level="j" type="abbrev">LANCET</title>
<idno type="ISSN">0140-6736</idno>
<imprint>
<publisher>ELSEVIER</publisher>
<date type="published" when="1999">1999</date>
<biblScope unit="volume">354</biblScope>
<biblScope unit="issue">9186</biblScope>
<biblScope unit="page" from="1277">1277</biblScope>
<biblScope unit="page" to="1282">1282</biblScope>
</imprint>
<idno type="ISSN">0140-6736</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0140-6736</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="Teeft" xml:lang="en">
<term>Acute otitis media</term>
<term>Antibiotic therapy</term>
<term>Antibody titres</term>
<term>Antigenic</term>
<term>Antigenic drift</term>
<term>Antigenic shift</term>
<term>Antigenic variation</term>
<term>Antiviral</term>
<term>Antiviral agents</term>
<term>Antiviral compounds</term>
<term>Antiviral drugs</term>
<term>Antiviral therapy</term>
<term>Asian influenza</term>
<term>Attenuated</term>
<term>Attenuated influenza vaccine</term>
<term>Cerebrospinal fluid</term>
<term>Chronic bronchitis</term>
<term>Clinical features</term>
<term>Clinical signs</term>
<term>Clinical trials</term>
<term>Control influenza</term>
<term>Cystic fibrosis</term>
<term>Diagnostic tests</term>
<term>Disease control</term>
<term>Early convalescence</term>
<term>Elderly adults</term>
<term>Elderly people</term>
<term>Engl</term>
<term>Excess deaths</term>
<term>Febrile</term>
<term>Febrile convulsions</term>
<term>Febrile illness</term>
<term>Gastrointestinal symptoms</term>
<term>Genetic reassortment</term>
<term>Haemagglutinin</term>
<term>Healthy adults</term>
<term>Hospital admission</term>
<term>Human disease</term>
<term>Immune response</term>
<term>Influenza</term>
<term>Influenza epidemics</term>
<term>Influenza infections</term>
<term>Influenza vaccination</term>
<term>Influenza vaccine</term>
<term>Influenza vaccines</term>
<term>Influenza virus</term>
<term>Influenza virus infection</term>
<term>Influenza virus vaccine</term>
<term>Influenza viruses</term>
<term>Laboratory diagnosis</term>
<term>Lancet</term>
<term>Large number</term>
<term>Master donor strains</term>
<term>Neuraminidase</term>
<term>Neuraminidase antigens</term>
<term>Neuraminidase genes</term>
<term>Neuraminidase inhibitors</term>
<term>Neuraminidase proteins</term>
<term>Novel haemagglutinin</term>
<term>Pandemic</term>
<term>Pregnant women</term>
<term>Renal failure</term>
<term>Resistant viruses</term>
<term>Respiratory syncytial virus</term>
<term>Serological diagnosis</term>
<term>Serum samples</term>
<term>Staphylococcus aureus</term>
<term>Subtypes</term>
<term>Syndrome</term>
<term>Toxic shock syndrome</term>
<term>Vaccination</term>
<term>Vaccine</term>
<term>Viral</term>
<term>Viral proteins</term>
<term>Virus</term>
<term>Virus infection</term>
<term>Virus infections</term>
<term>Virus isolation</term>
<term>Young adults</term>
<term>Young children</term>
<term>Zanamavir resistance</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">Summary: Influenza is the most frequent cause of acute respiratory illness requiring medical intervention because it affects all age groups and because it can recur in any individual. During the past three decades, efforts to prevent and control influenza have focused primarily on the use of inactivated influenza vaccines in elderly people and in individuals with chronic medical conditions that put them at risk for complications. However, the continuing impact of influenza in these and other population groups has motivated the development of novel approaches for prevention and control of influenza. Several important advances in the field of influenza have occurred in the last few years. An experimental live, attenuated, intranasally administered trivalent influenza vaccine was shown to be highly effective in protecting young children against influenza A H3N2 and influenza B. New antiviral drugs based on the structure of the neuraminidase molecule were assessed in clinical trials and found to be effective against influenza A and B viruses. The expected use of these new antiviral agents has accelerated the development of rapid point-of-care diagnostic tests. The availability of new diagnostic tests, new antiviral drugs, and new vaccines will undoubtedly alter our approaches to influenza control and have an impact on clinical practice.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Géorgie (États-Unis)</li>
</region>
</list>
<tree>
<country name="États-Unis">
<region name="Géorgie (États-Unis)">
<name sortKey="Cox, Nancy J" sort="Cox, Nancy J" uniqKey="Cox N" first="Nancy J" last="Cox">Nancy J. Cox</name>
</region>
<name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001996 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001996 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:E3DD38D50833B0C3308A0D61F6E108953AF09969
   |texte=   Influenza
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021